Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer : Nanodelivery Reaches Prime-Time?

Abstract EN

Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment.

We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer.

A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment.

This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.